Skip to main content
SpringerLink
Log in

Interferon Alpha

  • Chapter
Intraocular Inflammation

Abstract

Interferons (IFN) alpha and beta are naturally occurring cytokines, which belong to the type 1 interferons disclosing about 30 % homology of amino acid sequence. Both interferons are sharing the same receptor (an additional IFN-β receptor exists), so the therapeutic effect of these IFNs seems to be quite similar. They are induced by viral infections and tumors or foreign cells, exerting antiviral, antiproliferative, antiangiogenic, and immunomodulatory effects.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 299.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 379.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Alpsoy E, Durusoy C, Yilmaz E et al (2002) Interferon alfa-2a in the treatment of Behcet disease: a randomized placebo-controlled and double-blind study. Arch Dermatol 138:467–471

    CAS  PubMed  Google Scholar 

  2. Becker MD, Heiligenhaus A, Hudde T et al (2005) Interferon as a treatment for uveitis associated with multiple sclerosis. Br J Ophthalmol 89:1254–1257

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  3. Belardelli F, Gresser I (1996) The neglected role of type I interferon in the T-cell response: implications for its clinical use. Immunol Today 17:369–372

    Article  CAS  PubMed  Google Scholar 

  4. Bodaghi B, Gendron G, Wechsler B et al (2007) Efficacy of interferon alpha in the treatment of refractory and sight threatening uveitis: a retrospective monocentric study of 45 patients. Br J Ophthalmol 91:335–339

    Article  PubMed Central  PubMed  Google Scholar 

  5. Brasnu E, Wechsler B, Bron A et al (2005) Efficacy of interferon-alpha for the treatment of Kaposi’s sarcoma herpesvirus-associated uveitis. Am J Ophthalmol 140:746–748

    Article  CAS  PubMed  Google Scholar 

  6. Chi W, Zhu X, Yang P et al (2008) Upregulated IL-23 and IL-17 in Behcet’s Patients with active uveitis. Invest Ophthalmol Vis Sci 49:3058–3064

    Article  PubMed  Google Scholar 

  7. Conlon KC, Urba WJ, Smith JW et al (1990) Exacerbation of symptoms of autoimmune disease in patients receiving interferon-alpha therapy. Cancer 65:2237–2242

    Article  CAS  PubMed  Google Scholar 

  8. Deuter CME, Kötter I, Günaydin I et al (2006) Interferon alfa-2a: a new treatment option for long lasting refractory cystoid macular edema in uveitis? A pilot study. Retina 26:786–791

    Article  PubMed  Google Scholar 

  9. Deuter CM, Kötter I, Günaydin I et al (2009) Efficacy and tolerability of interferon alpha treatment in patients with chronic cystoid macular oedema due to non-infectious uveitis. Br J Ophthalmol 93:906–913

    Article  CAS  PubMed  Google Scholar 

  10. Doycheva D, Deuter CME, Stübiger N et al (2009) Interferon-alpha associated presumed ocular sarcoidosis. Graefes Arch Clin Exp Ophthalmol 247:675–680

    Article  CAS  PubMed  Google Scholar 

  11. Green AR, Vassilou GS, Curtin N et al (2004) Management of the myeloproliferative disorders: distinguishing data from dogma. Hematol J 5:126–132

    Article  Google Scholar 

  12. Gueudry J, Wechsler B, Terrada C et al (2008) Long-term efficacy and safety of low-dose interferon alpha2a therapy in severe uveitis associated with Behcet’s disease. Am J Ophthalmol 146:837–844

    Article  CAS  PubMed  Google Scholar 

  13. Guillaume-Czitrom E, Berger C, Pajot C et al (2007) Efficacy and safety of interferon-alpha in the treatment of corticodependent uveitis of paediatric Behcet’s disease. Rheumatology 46:1570–1573

    Article  CAS  PubMed  Google Scholar 

  14. Guney E, Akali G, Akcay BI et al (2012) Vitiligo in a patient treated with Interferon Alpha-2a for Behcet’s Disease. Case Rep Med. Epub ahead of print

    Google Scholar 

  15. Hamuryudan V, Ozyazgan Y, Fresko Y et al (2002) Interferon alfa combined with azathioprine for the uveitis of Behcet’s disease: an open study. Isr Med Assoc J 4:928–930

    CAS  PubMed  Google Scholar 

  16. Hatemi G, Bang D, Bodaghi B et al (2008) EULAR recommendations for the management of Behçet’s disease: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 67:1656–1662

    Article  CAS  PubMed  Google Scholar 

  17. Hoffmann A, Kim E, Krueger GR et al (1994) Bone marrow hypoplasia and fibrosis following interferon treatment. In Viva 8:605–612

    CAS  Google Scholar 

  18. Hurst EA, Mauro T (2005) Sarcoidosis associated with pegylated interferon alfa and ribavirin treatment for chronic hepatitis C: a case report and review of the literature. Arch Dermatol 141:865–868

    PubMed  Google Scholar 

  19. Imrie FR, Dick AD (2007) Biologicals in the treatment of uveitis. Curr Opin Ophthalmol 18:481–486

    Article  PubMed  Google Scholar 

  20. Kötter I, Günaydin I, Zierhut M et al (2004) The use of interferon alpha in Behcet’s disease: review of the literature. Semin Arthritis Rheum 33:320–335

    Article  PubMed  Google Scholar 

  21. Kötter I, Zierhut M, Eckstein AK et al (2003) Human recombinant interferon alfa-2a for the treatment of Behcet’s disease with sight threatening posterior or panuveitis. Br J Ophthalmol 87:423–431

    Article  PubMed Central  PubMed  Google Scholar 

  22. Krause L, Turnbull JR, Torun N et al (2003) Interferon alfa-2a in the treatment of ocular Adamantiades-Behçet’s disease. Adv Exp Med Biol 528:511–519

    Article  CAS  PubMed  Google Scholar 

  23. Liu X, Yang P, Wang C et al (2011) IFN-alpha blocks IL-17 production by peripheral blood mononuclear cells in Behcet’s disease. Rheumatology 50:293–298

    Article  CAS  PubMed  Google Scholar 

  24. Mackensen F, Jakob E, Springer C et al (2013) Interferon versus Methotrexate in intermediate uveitis with macular edema: results of a randomized controlled clinical trial. Am J Ophthalmol 156(3):478–486

    Google Scholar 

  25. Okada AA (2005) Immunomodulatory therapy for ocular inflammatory disease: a basic manual and review of the literature. Ocul Immunol Inflamm 13:335–351

    Article  CAS  PubMed  Google Scholar 

  26. Okada AA, Keino H, Fukai T et al (1998) Effect of type I interferon on experimental autoimmune uveoretinitis in rats. Ocul Immunol Inflamm 6:209–210

    Article  Google Scholar 

  27. Okada H, Pollack IF (2004) Cytokine gene therapy for malignant glioma. Expert Opin Biol Ther 4:1609–1620

    Article  CAS  PubMed  Google Scholar 

  28. Onal S, Kazokoglu H, Koc A et al (2011) Long-term efficacy and safety of low-dose and dose-escalating interferon alfa-2a therapy in refractory Behcet uveitis. Arch Ophthalmol 129:288–294

    Article  CAS  PubMed  Google Scholar 

  29. Physicians Desk Reference (2000) Medical Economics Company, Montvale, pp 2654–2658, 2808–2817

    Google Scholar 

  30. Plskova J, Greiner K, Muckersie E et al (2006) Interferon-alpha: a key factor in autoimmune disease? Invest Ophthalmol Vis Sci 47:3946–3950

    Article  PubMed  Google Scholar 

  31. Plskova J, Greiner K, Forrester JV (2007) Interferon-α as an effective treatment for noninfectious posterior uveitis and panuveitis. Am J Ophthalmol 144:55–61

    Article  CAS  PubMed  Google Scholar 

  32. Purvin VA (1995) Anterior ischemic optic neuropathy secondary to interferon alfa. Arch Ophthalmol 113:1041–1044

    Article  CAS  PubMed  Google Scholar 

  33. Saadeh S, Davis GL (2004) The evolving treatment of chronic hepatitis C: where we stand a decade out. Cleve Clin J Med 71:3–7

    Article  Google Scholar 

  34. Saito H, Ebinuma G, Satoh H et al (2000) Immunological and virological predictors of outcome during interferon-alpha therapy of chronic hepatitis C. J Viral Hepat 7:64–74

    Article  CAS  PubMed  Google Scholar 

  35. Sobaci G, Bayraktar Z, Bayer A (2005) Interferon alpha-2a treatment for serpiginous choroiditis. Ocul Immunol Inflamm 13:59–66

    Article  CAS  PubMed  Google Scholar 

  36. Sobaci G, Erdem U, Durukan AH et al (2010) Safety and effectiveness of interferon alpha-2a in treatment of patients with Behçet’s uveitis refractory to conventional treatments. Ophthalmology 117:1430–1435

    Article  PubMed  Google Scholar 

  37. Stoutenburg JP, Schrope B, Kaufmann HL (2004) Adjuvant therapy for malignant melanoma. Expert Rev Anticancer Ther 8:823–835

    Article  Google Scholar 

  38. Stübiger N, Kötter I, Deuter C et al (2001) Behcet’s disease: uveitis-therapy with interferon alpha2a—prospective clinical study in 33 patients. Klin Monbl Augenheilkd 528:768–773

    Article  Google Scholar 

  39. Stübiger N, Kötter I, Zierhut M (2000) Complete regression of retinal neovascularisation after therapy with interferon alfa in Behcet’s disease. Br J Ophthalmol 84:1437–1438

    Google Scholar 

  40. Stübiger N, Winterhalter S, Pleyer U et al (2011) Janus-faced? Effects and side effects of interferon therapy in ophthalmology. Ophthalmologe 108:204–212

    Article  PubMed  Google Scholar 

  41. Suzuki J, Sakai J, Okada AA et al (2002) Oral administration of interferon-beta suppresses experimental autoimmune uveoretinitis. Graefes Arch Clin Exp Ophthalmol 240:314–321

    Article  CAS  PubMed  Google Scholar 

  42. Tugal-Tutgun I, Guney-Tefekli E, Urgancioglu M (2006) Results of interferon-alfa therapy in patients with Behçet’s uveitis. Graefes Arch Clin Exp Ophthalmol 244:1692–1695

    Article  Google Scholar 

  43. Usui Y, Takeuchi M, Hattori T et al (2009) Suppression of experimental autoimmune uveoretinitis by regulatory dendritic cells in mice. Arch Ophthalmol 127:514–519

    Article  PubMed  Google Scholar 

  44. Vandenbark AA, Huan J, Agotsch M et al (2009) Interferon-beta-1a treatment increases CD56 (bright) natural killer cells and CD4 + CD25+ Foxp3 expression in subjects with multiple sclerosis. J Neuroimmunol 215:125–128

    Article  CAS  PubMed  Google Scholar 

  45. Yang DS, Galatowicz G, Calder VL et al (2009) Upregulation of Foxp3 expression by recombinant interferon-alpha therapy in Behcet’s disease. Poster No. 1535 ARVO 2009

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Universitätsmedizin Berlin, Campus Benjamin Franklin (CBF), Augenklinik, Hindenburgdamm 30, Berlin, 12200, Germany

    Nicole Stübiger

  2. Division of Ophthalmology, Centre of Ophthalmology, University of Tuebingen, Schleichstr. 12, Tuebingen, 72076, Germany

    Manfred Zierhut MD, PhD.

Authors
  1. Nicole Stübiger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Manfred Zierhut MD, PhD.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nicole Stübiger .

Editor information

Editors and Affiliations

  1. Centre of Ophthalmology, University of Tuebingen, Tuebingen, Germany

    Manfred Zierhut

  2. Biomedical Research Centre, Institute of Ophthalmology, Moorfields Eyes Hospital, Department of Medical Retina, UCL, London, United Kingdom

    Carlos Pavesio

  3. School of Medicine, Department of Ophthalmology, Hokkaido University Graduate, Sapporo, Hokkaido, Japan

    Shigeaki Ohno

  4. University of Belo Horizonte, Belo Horizonte, Brazil

    Fernando Orefice

  5. USC Eye Institute, University of Southern California, Los Angeles, California, USA

    Narsing A. Rao

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Stübiger, N., Zierhut, M. (2016). Interferon Alpha. In: Zierhut, M., Pavesio, C., Ohno, S., Orefice, F., Rao, N. (eds) Intraocular Inflammation. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-75387-2_27

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-75387-2_27

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-75385-8

  • Online ISBN: 978-3-540-75387-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation